In principle, if further tests bear out the protective effects of the two antibodies, then
optimized versions of them, or
small -
molecule drugs that hit the same target, could be developed as treatments for rhinovirus infections.
The Alzheimer's Innovation Award will help advance particularly critical components of Mucke's ongoing
drug discovery program to identify and
optimize small molecule compounds that potently and safely reduce tau levels in the brain.